Nucleic acid ligand diagnostic biochip

• US 6,458,543 B1
• Filed: 11/28/2000
• Issued: 10/01/2002
• Est. Priority Date: 12/15/1997
• Status: Expired due to Term

• Current Assignee: SomaLogic Operating Co., Inc. (Somalogic Incorporated)
• Original Assignee: Somalogic Incorporated
• Inventors: Gold, Larry, Drolet, Dan, Jayasena, Sumedha, Zichi, Dom, Gill, Stanley, Creighton, Steve
• Primary Examiner(s): Jones, W. Gary
• Assistant Examiner(s): FORMAN, BETTY J
• Application Number:
  US09/723,517
• Time in Patent Office: 672 Days
• Field of Search: 435/6, 435/287.2, 435/91.2, 435/287.1, 435/91.1, 435/174, 536/23.1, 536/25.4, 536/24.3, 422/68.1
• US Class Current: 435/6.11
• CPC Class Codes: C07B 2200/11 Compounds covalently bound to a solid support
• CPC Class Codes: C12Q 1/6834 Enzymatic or biochemical coupling of nucleic acids to a solid phase
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6839 Triple helix formation or other higher order conformations in hybridisation assays
• CPC Class Codes: C12Q 2525/205 Aptamer
• CPC Class Codes: C12Q 2541/101 Selex
• CPC Class Codes: C12Q 2565/101 Interaction between at least two labels
• CPC Class Codes: C12Q 2565/514 characterised by the use of the arrayed oligonucleotides as identifier tags, e.g. universal addressable array, anti-tag or tag complement array
• CPC Class Codes: C40B 40/00 Libraries per se, e.g. arrays, mixtures
• CPC Class Codes: Y10S 977/924 using nanostructure as support of dna analysis

Abstract

A Nucleic acid ligand “Biochip” is disclosed, consisting of a solid support to which one or more specific Nucleic acid ligands is attached in a spatially defined manner. Each Nucleic acid ligand binds specifically and avidly to a particular Target molecule contained within a Test mixture, such as a Bodily fluid. The Target molecules include, but are not limited to, proteins (cellular, viral, bacterial, etc.) hormones, sugars, metabolic byproducts, cofactor, and intermediates, drugs, and toxins. In principle, the Biochip could be used to test any chemically complex mixture provided that Nucleic acid ligands to components suspected of being present in the mixture are attached to the Biochip. Thus, the Nucleic acid ligand Biochip will have a wider use in environmental testing, etc.

Claims

1. A method for detecting a pattern of binding which identifies a disease or medical condition, the method comprising:

(a) identifying nucleic acid ligands to target molecules that may be indicative of a disease and/or medical condition;

(b) binding said nucleic acid ligands to spatially discrete locations on a solid support;

(c) contacting said solid support with biological sample solutions that may comprise said target molecules from individuals with and without said disease or medical condition to thereby bind target molecules to nucleic acid ligands on said solid support;

(d) detecting the pattern of binding of said target molecules contained within biological sample solutions obtained from individuals with and without said disease or medical condition; and

(e) comparing the patterns of binding detected in step (d), whereby a pattern of binding which identifies said disease or medical condition is detected.

2. A method for detecting a target molecule in a test mixture, the method comprising:

(a) preparing a biochip, the biochip comprising a solid support, said support comprising a plurality of spatially defined addresses, each said address having at least one copy of a single species of nucleic acid ligand attached thereto, each said species of nucleic acid ligand having specific affinity for one of said target molecules suspected of being contained in said test mixture, and each said species of nucleic acid ligand binding to said target molecule through non-Watson-Crick interactions;

(b) contacting said biochip with said test mixture; and

(c) detecting and measuring the amount of said target molecule bound to said biochip at one or more of said addresses.